A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Subjects With Extensive Stage Small Cell Lung Cancer (MERU)
Phase of Trial: Phase III
Latest Information Update: 12 Aug 2018
At a glance
- Drugs Rovalpituzumab tesirine (Primary) ; Dexamethasone
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms MERU
- Sponsors AbbVie
- 31 Jul 2018 Planned End Date changed from 30 Aug 2020 to 31 Aug 2020.
- 28 Feb 2018 Planned End Date changed from 1 Apr 2020 to 30 Aug 2020.
- 18 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.